VistaGen Therapeutics (NASDAQ:VTGN) Rating Lowered to “Sell” at Wall Street Zen

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other analysts also recently commented on VTGN. Jefferies Financial Group reissued a “hold” rating and set a $0.90 price objective (down previously from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research report on Wednesday. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday. William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Price Performance

Shares of VTGN stock opened at $0.78 on Friday. The business’s fifty day moving average price is $4.00 and its 200 day moving average price is $3.27. VistaGen Therapeutics has a 1-year low of $0.68 and a 1-year high of $5.14. The firm has a market capitalization of $30.72 million, a PE ratio of -0.41 and a beta of 0.56.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. Equities research analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VistaGen Therapeutics

Large investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC increased its position in VistaGen Therapeutics by 246.4% during the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after buying an additional 299,304 shares in the last quarter. AdvisorShares Investments LLC boosted its stake in shares of VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after acquiring an additional 44,000 shares during the last quarter. Boothbay Fund Management LLC boosted its stake in shares of VistaGen Therapeutics by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock valued at $699,000 after acquiring an additional 19,166 shares during the last quarter. Two Sigma Investments LP increased its position in VistaGen Therapeutics by 223.5% during the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after purchasing an additional 199,958 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in VistaGen Therapeutics in the 3rd quarter valued at about $112,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.